CSIMarket
 
Pharvaris N v   (PHVS)
Other Ticker:  
 
 
Price: $23.3500 $-0.33 -1.394%
Day's High: $23.88 Week Perf: -0.98 %
Day's Low: $ 22.93 30 Day Perf: -11.15 %
Volume (M): 119 52 Wk High: $ 33.00
Volume (M$): $ 2,788 52 Wk Avg: $18.15
Open: $23.43 52 Wk Low: $6.25



 Market Capitalization (Millions $) 785
 Shares Outstanding (Millions) 34
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -85
 Cash Flow (TTM) (Millions $) 234
 Capital Exp. (TTM) (Millions $) 0

Pharvaris N V
Pharvaris N v refers to a specific legal case involving Pharvaris, a biopharmaceutical company, as the plaintiff. The N v generally denotes a lawsuit where the defendant is not specified or is yet to be determined. Therefore, Pharvaris N v indicates that Pharvaris is the plaintiff in a pending legal action or lawsuit, but the specific details or parties involved in the case are not provided.


   Company Address: Emmy Noetherweg 2 Leiden 2333
   Company Phone Number: 71 2036 410   Stock Exchange / Ticker: NASDAQ PHVS
   PHVS is expected to report next financial results on April 04, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Pharvaris Advances Potential Breakthrough in HAE Treatment with Novel Oral Therapy

Published Mon, Mar 18 2024 10:50 AM UTC

Pharvaris, a leading biopharmaceutical company focused on developing innovative oral bradykinin B2 receptor antagonists for the treatment and prevention of hereditary angioedema (HAE) attacks, recently presented promising data from multiple clinical studies at renowned medical congresses. These findings highlight the potential of their investigational drug deucrictibant as a...

Clinical Study

Pharvaris to Present Groundbreaking Data on Oral HAE Medications at International Congresses

Published Wed, Mar 6 2024 11:50 AM UTC

Pharvaris, a clinical-stage biopharmaceutical company, has announced that it will be presenting clinical data on their novel oral bradykinin B2 receptor antagonists at two upcoming congresses. The abstracts have been accepted for presentation at the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA), which will be held from March 14-1...

Clinical Study

Pharvaris Presents Pivotal HAE Treatment Data: A New Dawn in On-demand Therapy?

Published Fri, Dec 8 2023 11:00 PM UTC


Swiss biotech firm Pharvaris has made a significant advance in the field of hereditary angioedema (HAE) treatments, recently showcasing its clinical data and analysis of Deucrictibant for on-demand treatment of HAE at the GALEN Urticaria Centers of Reference and Excellence (UCARE) Conference 2023 in S?o Paulo, Brazil.
Pharvaris, a clinical-stage company listed on th...

Shares

Pharvaris Prices $300 Million Offering of Ordinary Shares and Pre-funded Warrants to Advance Treatment for Hereditary Angioedema

Published Wed, Dec 6 2023 12:02 PM UTC


ZUG, Switzerland, Dec. 06, 2023 - Pharvaris N.V. (Nasdaq: PHVS), a clinical-stage biopharmaceutical company specializing in the development of novel oral bradykinin B2 receptor antagonists for addressing hereditary angioedema (HAE) attacks, announced today the pricing of an underwritten offering of its ordinary shares and pre-funded warrants.
Under this offering, Ph...

Clinical Study

Deucrictibant: A Potential Game-Changer in Preventative Treatment for Hereditary Angioedema

Published Wed, Dec 6 2023 11:50 AM UTC



ZUG, Switzerland - Pharvaris (Nasdaq: PHVS), a clinical-stage company dedicated to developing novel, oral bradykinin B2 receptor antagonists for the treatment and prevention of hereditary angioedema (HAE) attacks, has recently released positive top-line data from their CHAPTER-1 Phase 2 clinical study. This successful study marks a significant milestone in the deve...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com